Fort Lauderdale, FL – According to filings with the U.S. Securities and Exchange Commission, Psycheceutical Biosciences is raising $6,500,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Chad Harman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Psycheceutical Biosciences
At Psycheceutical Biosciences were removing barriers to care by employing state-of-the-art patented delivery technologies to provide safe and effective psychedelic pharmaceutical medicines. Our visionary team of industry experts has 100+ years of combined experience in psychedelics, biotechnology, and business development across the pharmaceutical industry. Our visionary founders are considered among the top minds in the psychedelic space, embracing the latest technologies to further the advancement of mental health science. Our groundbreaking Janus particle solution and NeuroDirect delivery system allow psychedelic compounds to be administered without unwanted side effects and toxicity.

To learn more about Psycheceutical Biosciences, visit http://psycheceutical.com/

Contact:
Chad Harman, Chief Executive Officer
303-507-5538
chad.harman@psycheceutical.com
https://www.linkedin.com/in/chad-harman-a287b7137/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved